Biogen, Eisai Alzheimer's drug Leqembi covered by VA
Spencer Platt/Getty Images News


Veterans living with Alzheimer's disease will have access to Biogen (NASDAQ:BIIB) and Eisai's (OTCPK:ESALF)(OTCPK:ESAIY) Alzheimer's drug Leqembi (lecanemab) through the Veterans Health Administration.
The move is somewhat of a surprise given that CMS in February said it was not reconsidering a decision made last year to severely limit coverage of amyloid-targeting Alzheimer's antibody therapies.

Leqembi can be prescribed by VA healthcare professionals to vets based on the agency's criteria and the drug's label. The latter says the treatment is limited to those with early-stage disease.
Leqembi was approved under accelerated approval in January. Eisai (OTCPK:ESAIY) is also pursuing traditional approval, a prospect that could help win CMS and private payer coverage, and which could come this summer, according to the Japanese pharma's US CEO.